OA: Chemoresistance and targeted therapies in ovarian and endometrial cancers | Brasseur | Oncotarget

open access

 In this manuscript, we will review the current treatments, their limitations against gynecological cancers and the molecular pathways responsible for the acquired chemoresistance thus leading to the current use of targeted therapies in clinical trials to increase the efficiency of treatments, which prevents recurrent cancers and increases survival of women suffering from these types of cancers